Skip to main content

Infographic | On the Path to Compliance: An EU Action Plan Timeline

Posted on December 8, 2022

Curtis File
Curtis File
Editorial Manager, ESG and Sustainable Finance

The implementation of the EU Action Plan’s regulatory framework is underway and financial market participants must manage multiple, fast-approaching deadlines for compliance.  

Under the plan, investors must adhere to several new sustainability-driven regulations including the EU Taxonomy, the Sustainable Finance Disclosure Regulation (SFDR), and the Markets in Financial Instruments Directive II (MiFID II).  

We’ve created an infographic that provides an overview of important compliance milestones for the EU Action Plan. Read on to see when your firm needs to comply.  

Access a PDF version by clicking the image or by downloading it here

Learn more about the EU Action Plan, its objectives, and to whom it applies by reading our ebook, The EU Action Plan on Financing Sustainable Growth: Twelve Essential Questions Answered for Investors.

An infographic featuring a timeline of important compliance dates for the EU Action Plan on Financing Sustainable Growth

Recent Content

Tire Supply Chains Face Rising Deforestation Risks as Traceability Requirements Tighten

Exploring how deforestation regulations and traceability requirements are reshaping natural rubber sourcing and ESG risks across tire supply chains.

Frameworks in Focus: Comparing NZIF 2.0 and SBTi Net Zero Standard for Financial Institutions

This article provides a comparison of NZIF 2.0 and the SBTi Net Zero Standard for Financial Institutions, and explores what they reveal about portfolio alignment, and climate transition strategies for asset owners and asset managers.

Heat, Policy and Portfolios: What This Summer's Climate Moment Revealed About Investor Priorities

Exploring how climate transition, nature investing and physical risk are reshaping investor priorities and portfolio strategies in a changing market.

US, Europe Biopharma Partnerships With Chinese Firms: Evaluating ESG Risks

Examining the ESG and geopolitical risks shaping US and European biopharma partnerships with Chinese firms.